Marcos Tadashi Kakitani Toyoshima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcos Tadashi Kakitani Toyoshima has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Márcia Nery
Department of Endocrinology and Metabolism, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
6 shared publications - Alina Coutinho Rodrigues Feitosa
Faculty of Medicine, Zarns, Brazil
3 shared publications Ana O. Hoff
3 shared publications- Ana Oliveira Hoff
Instituto do Câncer do Estado de São Paulo Faculdade de Medicina da Universidade de São Paulo São Paulo São Paulo Brazil
3 shared publications Dawn Smiley
Department of Medicine , Emory University School of Medicine , Atlanta, Georgia , USA
3 shared publications- Guillermo E. Umpierrez
Medicine, Emory University, Atlanta, Georgia, USA
3 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in AACE Endocrinology and Diabetes
- Vol. 13 (5) , 679-684
Management and Follow-up of Sporadic Cribriform-Morular Thyroid Carcinoma After the 2022 World Health Organization Reclassification
- 14 May 2026
- Published by Elsevier in AACE Endocrinology and Diabetes
- Vol. 13 (5) , 679-684
Open AccessManagement and Follow-up of Sporadic Cribriform-Morular Thyroid Carcinoma After the 2022 World Health Organization Reclassification
- 30 January 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (6) , 990-1000
Glucocorticoid-Induced Hyperglycemia in Patients With Cancer: Mechanisms, Clinical Implications, and Management Strategies
- 30 January 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (6) , 990-1000
Glucocorticoid-Induced Hyperglycemia in Patients With Cancer: Mechanisms, Clinical Implications, and Management Strategies
- Open Access
- 1 September 2025
- Vol. 23, eRC1400
Atrophic hypothyroidism associated with thyrotropin receptor antibodies.
Hypothyroidism is most frequently caused by Hashimoto's thyroiditis. While thyrotropin receptor antibodies are well-known in Graves' disease-induced hyperthyroidism, their role in hypothyroidism is emerging. We report the case of a 37-year-old woman with facial and periorbital edema, weight gain, and hoarseness suggestive of hypothyroidism. Elevated thyroid stimulating hormone (TSH; 131mIU/L) and decreased free thyroxine (0.2ng/dL, 2.6pmol/L) levels confirmed this diagnosis. Laboratory findings showed dyslipidemia, impaired renal function, elevated creatine phosphokinase levels, and anemia. Despite negative results for thyroid peroxidase (TPO-Ab) and thyroglobulin (TgAb) antibodies, positive thyrotropin receptor antibodies (11IU/L) suggested an autoimmune etiology. Thyroid ultrasound confirmed atrophic thyroiditis. Levothyroxine treatment improved the symptoms and laboratory values. Two months after diagnosis, the patient became pregnant. Anemia relapsed during pregnancy, thyrotropin receptor antibodies levels normalized, and postpartum follow-up revealed stable thyroid function without affecting the newborn thyroid function. This case underscores the diagnostic challenges of negative TPOAb and TgAb hypothyroidism, which is often misdiagnosed as Hashimoto's thyroiditis, and highlights the need for functional discrimination in thyrotropin receptor antibodies assays. Thyrotropin receptor antibodies measurements can help in the differential diagnosis of rapidly evolving hypothyroidism in women with negative TPO-Ab and thyrotropin receptor antibodies levels, especially in women of childbearing age. Further research is essential to understand thyrotropin-binding inhibitory immunoglobulin-mediated hypothyroidism and to develop targeted therapies.
- 1 September 2025
- Vol. 23, eRC1400
Open AccessAtrophic hypothyroidism associated with thyrotropin receptor antibodies.
Hypothyroidism is most frequently caused by Hashimoto's thyroiditis. While thyrotropin receptor antibodies are well-known in Graves' disease-induced hyperthyroidism, their role in hypothyroidism is emerging. We report the case of a 37-year-old woman with facial and periorbital edema, weight gain, and hoarseness suggestive of hypothyroidism. Elevated thyroid stimulating hormone (TSH; 131mIU/L) and decreased free thyroxine (0.2ng/dL, 2.6pmol/L) levels confirmed this diagnosis. Laboratory findings showed dyslipidemia, impaired renal function, elevated creatine phosphokinase levels, and anemia. Despite negative results for thyroid peroxidase (TPO-Ab) and thyroglobulin (TgAb) antibodies, positive thyrotropin receptor antibodies (11IU/L) suggested an autoimmune etiology. Thyroid ultrasound confirmed atrophic thyroiditis. Levothyroxine treatment improved the symptoms and laboratory values. Two months after diagnosis, the patient became pregnant. Anemia relapsed during pregnancy, thyrotropin receptor antibodies levels normalized, and postpartum follow-up revealed stable thyroid function without affecting the newborn thyroid function. This case underscores the diagnostic challenges of negative TPOAb and TgAb hypothyroidism, which is often misdiagnosed as Hashimoto's thyroiditis, and highlights the need for functional discrimination in thyrotropin receptor antibodies assays. Thyrotropin receptor antibodies measurements can help in the differential diagnosis of rapidly evolving hypothyroidism in women with negative TPO-Ab and thyrotropin receptor antibodies levels, especially in women of childbearing age. Further research is essential to understand thyrotropin-binding inhibitory immunoglobulin-mediated hypothyroidism and to develop targeted therapies.
- Open Access
- 25 June 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 103 (4) , 605-611
Endocrine Implications of Thyroid Incidentalomas Detected During Lymphoma Staging With 18F‐Fluorodeoxyglucose Positron Emission Tomography
Objective: This study investigated the prevalence, characteristics, and endocrine implications of thyroid incidentalomas detected during lymphoma staging using FDG‐PET/CT.Design: Retrospective cohort study.Patients: A total of 795 adult patients with lymphoma who underwent FDG‐PET/CT for staging at a tertiary oncology centre were included.Measurements: Thyroid uptake was classified as focal, diffuse, or absent. Additional data included demographic features, lymphoma subtype, thyroid function, autoantibodies, ultrasound (US), fine‐needle aspiration cytology (FNAC), and histopathology when available.Results: Thyroid abnormalities were detected in 139 patients (17.5%). Focal FDG uptake was observed in 33 patients (4.2%) and was associated with a malignancy rate of 18.2% (28.6% among those who underwent FNAC). Diffuse uptake was observed in 20 patients (2.5%) and was significantly associated with positive thyroid autoantibodies (58.3%, p < 0.01). Older age and female gender were independent predictors of thyroid uptake. ROC analysis identified optimal age thresholds of 68.6 years for females and 59.8 years for males (AUC = 0.72). SUVmax, Hounsfield units, and ACR TI‐RADS classification were not significantly associated with malignancy. All malignant cases occurred in nodules classified as TI‐RADS 4 or 5. Volume on CT was inversely associated with malignancy (ρ = –0.50, p = 0.046). No significant impact on overall survival was observed.Conclusions: Thyroid incidentalomas are frequent during lymphoma staging by FDG‐PET/CT and should be appropriately evaluated. Focal uptake carries a relevant malignancy risk, even in nodules with low SUVmax. Diffuse uptake often reflects autoimmune thyroiditis. A multimodal diagnostic approach is essential to guide management and avoid unnecessary delays in cancer care.
- 25 June 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 103 (4) , 605-611
Open AccessEndocrine Implications of Thyroid Incidentalomas Detected During Lymphoma Staging With 18F‐Fluorodeoxyglucose Positron Emission Tomography
Objective: This study investigated the prevalence, characteristics, and endocrine implications of thyroid incidentalomas detected during lymphoma staging using FDG‐PET/CT.Design: Retrospective cohort study.Patients: A total of 795 adult patients with lymphoma who underwent FDG‐PET/CT for staging at a tertiary oncology centre were included.Measurements: Thyroid uptake was classified as focal, diffuse, or absent. Additional data included demographic features, lymphoma subtype, thyroid function, autoantibodies, ultrasound (US), fine‐needle aspiration cytology (FNAC), and histopathology when available.Results: Thyroid abnormalities were detected in 139 patients (17.5%). Focal FDG uptake was observed in 33 patients (4.2%) and was associated with a malignancy rate of 18.2% (28.6% among those who underwent FNAC). Diffuse uptake was observed in 20 patients (2.5%) and was significantly associated with positive thyroid autoantibodies (58.3%, p < 0.01). Older age and female gender were independent predictors of thyroid uptake. ROC analysis identified optimal age thresholds of 68.6 years for females and 59.8 years for males (AUC = 0.72). SUVmax, Hounsfield units, and ACR TI‐RADS classification were not significantly associated with malignancy. All malignant cases occurred in nodules classified as TI‐RADS 4 or 5. Volume on CT was inversely associated with malignancy (ρ = –0.50, p = 0.046). No significant impact on overall survival was observed.Conclusions: Thyroid incidentalomas are frequent during lymphoma staging by FDG‐PET/CT and should be appropriately evaluated. Focal uptake carries a relevant malignancy risk, even in nodules with low SUVmax. Diffuse uptake often reflects autoimmune thyroiditis. A multimodal diagnostic approach is essential to guide management and avoid unnecessary delays in cancer care.
- Open Access
- 10 May 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-5
A decade of InsulinAPP: validation using COSMIN and clinical advancements since its initial publication
This correspondence marks the 10-year milestone of InsulinAPP, a Brazilian-developed electronic glycemic management system (eGMS) designed to support inpatient insulin therapy. Initially published in 2015, InsulinAPP was developed to assist non-specialist physicians in applying evidence-based insulin protocols in hospital settings. Over the past decade, it has evolved into a validated clinical decision-support tool with demonstrated impact across multiple care contexts. In this manuscript, we present a structured overview of its validation using the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) framework, assessing five core domains: cross-cultural adaptation, content validity, criterion validity, reliability, and construct validity. Usability testing showed high acceptance (mean Likert score 4.8/5), and expert consensus on content validity was strong (Content Validity Index = 0.95). The tool also demonstrated high reproducibility (intraclass correlation coefficient = 0.98), and in a randomized trial, glycemic control with InsulinAPP was comparable to endocrinologist-led care, with low hypoglycemia rates. Compared to other eGMS solutions, InsulinAPP stands out for its simplicity, independence from electronic health record integration, and adaptability to low-resource environments. Its protocol anticipated updates later adopted by the Endocrine Society and the Brazilian Diabetes Society, particularly regarding stratified insulinization for patients with mild-to-moderate hyperglycemia. Together, these findings confirm InsulinAPP’s scientific soundness, safety, and real-world applicability. Broader implementation and multicenter studies are warranted to further explore its impact in diverse healthcare systems and improve access to safe inpatient glycemic management.
- 10 May 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-5
Open AccessA decade of InsulinAPP: validation using COSMIN and clinical advancements since its initial publication
This correspondence marks the 10-year milestone of InsulinAPP, a Brazilian-developed electronic glycemic management system (eGMS) designed to support inpatient insulin therapy. Initially published in 2015, InsulinAPP was developed to assist non-specialist physicians in applying evidence-based insulin protocols in hospital settings. Over the past decade, it has evolved into a validated clinical decision-support tool with demonstrated impact across multiple care contexts. In this manuscript, we present a structured overview of its validation using the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) framework, assessing five core domains: cross-cultural adaptation, content validity, criterion validity, reliability, and construct validity. Usability testing showed high acceptance (mean Likert score 4.8/5), and expert consensus on content validity was strong (Content Validity Index = 0.95). The tool also demonstrated high reproducibility (intraclass correlation coefficient = 0.98), and in a randomized trial, glycemic control with InsulinAPP was comparable to endocrinologist-led care, with low hypoglycemia rates. Compared to other eGMS solutions, InsulinAPP stands out for its simplicity, independence from electronic health record integration, and adaptability to low-resource environments. Its protocol anticipated updates later adopted by the Endocrine Society and the Brazilian Diabetes Society, particularly regarding stratified insulinization for patients with mild-to-moderate hyperglycemia. Together, these findings confirm InsulinAPP’s scientific soundness, safety, and real-world applicability. Broader implementation and multicenter studies are warranted to further explore its impact in diverse healthcare systems and improve access to safe inpatient glycemic management.
- Open Access
- 7 May 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250164
Comparison between computer-guided and conventional paper-based insulin infusion protocols in the treatment of acute hyperglycemic syndromes: an observational study
Acute hyperglycemic syndrome (AHS), including diabetic ketoacidosis (DKA) and a hyperosmolar hyperglycemic state (HHS), is a critical emergency requiring prompt and effective management. Intravenous insulin therapy is the cornerstone of treatment. Electronic glucose management systems (eGMSs) are increasingly used in treating AHS,()demonstrating positive outcomes such as the resolution of AHS(,)and a reduction in the incidence […] Acute hyperglycemic syndrome (AHS), including diabetic ketoacidosis (DKA) and a hyperosmolar hyperglycemic state (HHS), is a critical emergency requiring prompt and effective management. Intravenous insulin therapy is the cornerstone of treatment. Electronic glucose management systems (eGMSs) are increasingly used in treating AHS,()demonstrating positive outcomes such as the resolution of AHS(,)and a reduction in the incidence […]
- 7 May 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250164
Open AccessComparison between computer-guided and conventional paper-based insulin infusion protocols in the treatment of acute hyperglycemic syndromes: an observational study
Acute hyperglycemic syndrome (AHS), including diabetic ketoacidosis (DKA) and a hyperosmolar hyperglycemic state (HHS), is a critical emergency requiring prompt and effective management. Intravenous insulin therapy is the cornerstone of treatment. Electronic glucose management systems (eGMSs) are increasingly used in treating AHS,()demonstrating positive outcomes such as the resolution of AHS(,)and a reduction in the incidence […] Acute hyperglycemic syndrome (AHS), including diabetic ketoacidosis (DKA) and a hyperosmolar hyperglycemic state (HHS), is a critical emergency requiring prompt and effective management. Intravenous insulin therapy is the cornerstone of treatment. Electronic glucose management systems (eGMSs) are increasingly used in treating AHS,()demonstrating positive outcomes such as the resolution of AHS(,)and a reduction in the incidence […]
- 3 August 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (2) , 308-316
Electronic Glycemic Management System Improved Glycemic Control and Reduced Complications in Patients With Diabetes Undergoing Coronary Artery Bypass Surgery: A Randomized Controlled Trial
Background: In-hospital hyperglycemia poses significant risks for patients with diabetes mellitus undergoing coronary artery bypass graft (CABG) surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP offer promise in standardizing and improving glycemic control (GC) in these settings. This study evaluated the efficacy of the InsulinAPP protocol in optimizing GC and reducing adverse outcomes post-CABG. Methods: This prospective, randomized, open-label study was conducted with 100 adult type 2 diabetes mellitus (T2DM) patients post-CABG surgery, who were randomized into two groups: conventional care (gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin therapy management, whereas the gCONV received standard clinical care. The primary outcome was a composite of hospital-acquired infections, renal function deterioration, and symptomatic atrial arrhythmia. Secondary outcomes included GC, hypoglycemia incidence, hospital stay length, and costs. Results: The gAPP achieved lower mean glucose levels (167.2 ± 42.5 mg/dL vs 188.7 ± 54.4 mg/dL; P = .040) and fewer patients-day with BG above 180 mg/dL (51.3% vs 74.8%, P = .011). The gAPP received an insulin regimen that included more prandial bolus and correction insulin (either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs 16.7%). The primary composite outcome occurred in 16% of gAPP patients compared with 58% in gCONV ( P < .010). Hypoglycemia incidence was lower in the gAPP (4% vs 16%, P = .046). The gAPP protocol also resulted in shorter hospital stays and reduced costs. Conclusions: The InsulinAPP protocol effectively optimizes GC and reduces adverse outcomes in T2DM patients’ post-CABG surgery, offering a cost-effective solution for inpatient diabetes management.
- 3 August 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (2) , 308-316
Electronic Glycemic Management System Improved Glycemic Control and Reduced Complications in Patients With Diabetes Undergoing Coronary Artery Bypass Surgery: A Randomized Controlled Trial
Background: In-hospital hyperglycemia poses significant risks for patients with diabetes mellitus undergoing coronary artery bypass graft (CABG) surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP offer promise in standardizing and improving glycemic control (GC) in these settings. This study evaluated the efficacy of the InsulinAPP protocol in optimizing GC and reducing adverse outcomes post-CABG. Methods: This prospective, randomized, open-label study was conducted with 100 adult type 2 diabetes mellitus (T2DM) patients post-CABG surgery, who were randomized into two groups: conventional care (gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin therapy management, whereas the gCONV received standard clinical care. The primary outcome was a composite of hospital-acquired infections, renal function deterioration, and symptomatic atrial arrhythmia. Secondary outcomes included GC, hypoglycemia incidence, hospital stay length, and costs. Results: The gAPP achieved lower mean glucose levels (167.2 ± 42.5 mg/dL vs 188.7 ± 54.4 mg/dL; P = .040) and fewer patients-day with BG above 180 mg/dL (51.3% vs 74.8%, P = .011). The gAPP received an insulin regimen that included more prandial bolus and correction insulin (either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs 16.7%). The primary composite outcome occurred in 16% of gAPP patients compared with 58% in gCONV ( P < .010). Hypoglycemia incidence was lower in the gAPP (4% vs 16%, P = .046). The gAPP protocol also resulted in shorter hospital stays and reduced costs. Conclusions: The InsulinAPP protocol effectively optimizes GC and reduces adverse outcomes in T2DM patients’ post-CABG surgery, offering a cost-effective solution for inpatient diabetes management.